卵巢癌
肿瘤科
内科学
浆液性液体
癌基因
疾病
人类白细胞抗原
癌症
医学
生物
免疫学
抗原
细胞周期
作者
Yanrong Li,Haixia Li,Bob Yang,Jing Wei,Zhiyong Cheng,Limin Feng
出处
期刊:Translational cancer research
[AME Publishing Company]
日期:2020-02-01
卷期号:9 (2): 466-476
被引量:9
标识
DOI:10.21037/tcr.2019.11.30
摘要
The outcomes of ovarian cancer patients are very poor, therefore it is necessary to find prognostic biomarkers and explore the potential underlying molecular mechanisms of ovarian cancer.In this study, a gene expression microarray data set covering 562 ovarian serous cystadenocarcinomas and 12,042 genes was downloaded from The Cancer Genome Atlas (TCGA) database. For each candidate gene, samples were allocated into a "high group" or a "low group" according to the expression level. The overall survival (OS) rates were compared between the two groups. Then, a univariate analysis and a multivariate Cox proportional hazards test were carried out to examine the associations between genes and multiple clinicopathological parameters.Among all candidate genes, PI3 (peptidase inhibitor 3, often called elafin) and HLA-DOB (major histocompatibility complex, class II, DO beta) were identified as hub genes. PI3 (P=7.99e-7) and HLA-DOB (P=7.52e-6) showed significant associations with OS, especially in patients with stage III or IV disease. Both PI3 (HR =1.84, P=3.77e-7) and HLA-DOB (HR =0.68, P=0.001134) were identified as independent predictors of ovarian cancer patients OS. In addition, IRF1 (interferon regulatory factor 1) (P=1.16e-15) and SPI1 (Spi-1 proto-oncogene) (P=2.03e-6) were identified as the most significant transcription factors.Our data indicate that PI3 and HLA-DOB are potential biomarkers that could be used to predict the prognosis of ovarian cancer patients, and may play important roles in ovarian cancer progression. Further experimental and clinical studies with larger sample sizes are needed to confirm these findings.
科研通智能强力驱动
Strongly Powered by AbleSci AI